BioCardia (BCDA) Projected to Post Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. On average, analysts expect BioCardia to post ($0.71) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

BioCardia Price Performance

Shares of NASDAQ:BCDA opened at $0.92 on Wednesday. BioCardia has a 12 month low of $0.75 and a 12 month high of $1.80. The firm has a market capitalization of $13.95 million, a P/E ratio of -1.44 and a beta of 0.69. The company’s fifty day moving average price is $1.04 and its 200 day moving average price is $1.07.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating on shares of BioCardia in a report on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioCardia presently has an average rating of “Hold” and an average price target of $25.00.

About BioCardia

BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy.

BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.